**Summary**
Avacta Group PLC, a life sciences company focused on developing targeted oncology drugs, announced on September 9, 2025, that its pre
CISION® platform has been shortlisted for the *Technology of the Year Award* at the AIM Awards. The AIM Awards, held annually in London, celebrate achievements among the world’s fas<mark style="background-color:yellow">test</mark>-growing publicly quoted companies. Avacta’s pre
CISION® technology is a proprietary payload delivery system designed to target cancer cells while minimizing harm to healthy tissues, improving patient outcomes. CEO Christina Coughlin expressed pride in the recognition and highlighted the platform’s potential to revolutionize cancer therapy delivery. The awards ceremony is scheduled for October 1, 2025.
**Key Points**
Avacta’s pre
CISION® platform shortlisted for AIM Awards *Technology of the Year*.
The platform delivers potent cancer therapies with reduced systemic toxicity.
AIM Awards celebrate growth and innovation among publicly quoted companies.
Awards ceremony to take place on October 1, 2025.